{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:24:05Z","timestamp":1783949045686,"version":"3.55.0"},"reference-count":43,"publisher":"The Journal of Rheumatology","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>We aimed to investigate demographic and clinical features and predictors of mortality in Korean patients with systemic sclerosis (SSc).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>We performed a retrospective multicenter medical chart review in Korean patients diagnosed with SSc from 1986 to 2016 at 11 university hospitals representing each geographic area of Korea. SSc patients were defined according to the American College of Rheumatology preliminary classification criteria and subtyped as limited cutaneous (lcSSc) or diffuse cutaneous (dcSSc) SSc.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>We enrolled 751 patients (female, 86.7%; mean age at diagnosis, 48.9 yrs). The most common organ involvement was interstitial lung disease (52.7%), followed by gastroesophageal reflux disease (32.9%) and pulmonary arterial hypertension (13.6%). Patients with lcSSc were more common than those with dcSSc (64.8 vs 35.2%), whereas anti-Scl-70 and anticentromere antibody positivity were identified in 302 (42.5%) and 175 (25.5%) patients, respectively. In the 46 (6.1%) patients who developed a malignancy, lung cancer (23.9%) was the most common diagnosis, followed by gastric (13%) and breast cancer (13%). During the study period, 57 (7.6%) patients died, and the 5- and 10-year survival rates were 94% and 87%, respectively. Increased age at diagnosis, cardiovascular involvement, and anti-Scl-70 antibody positivity were significant predictors of death.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Clinical manifestations and survival rates in Korean SSc patients are similar to those of other populations. However, the prevalence of anti-Scl-70 antibody is higher in Korean SSc patients compared with whites, while the prevalence of anticentromere antibody is lower.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.171443","type":"journal-article","created":{"date-parts":[[2018,7,15]],"date-time":"2018-07-15T11:25:11Z","timestamp":1531653911000},"page":"1281-1288","source":"Crossref","is-referenced-by-count":27,"title":["Clinical and Laboratory Characteristics and Mortality in Korean Patients with Systemic Sclerosis: A Nationwide Multicenter Retrospective Cohort Study"],"prefix":"10.3899","volume":"45","author":[{"given":"Ki Won","family":"Moon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Jong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Bum","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Jin","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hyeon","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Hae","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Ah","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Young","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Bong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Geun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2018,7,15]]},"reference":[{"key":"2018112909385987000_45.9.1281.1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5301\/jsrd.5000249","article-title":"Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities","volume":"2","author":"Varga","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"2018112909385987000_45.9.1281.2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200203000-00004"},{"key":"2018112909385987000_45.9.1281.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.11.003"},{"key":"2018112909385987000_45.9.1281.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.091348"},{"key":"2018112909385987000_45.9.1281.5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.5301\/jsrd.5000256","article-title":"What have multicentre registries across the world taught us about the disease features of systemic sclerosis?","volume":"2","author":"Proudman","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"2018112909385987000_45.9.1281.6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken179"},{"key":"2018112909385987000_45.9.1281.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.10.004"},{"key":"2018112909385987000_45.9.1281.8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120283"},{"key":"2018112909385987000_45.9.1281.9","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111582"},{"key":"2018112909385987000_45.9.1281.10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/34.6.104"},{"key":"2018112909385987000_45.9.1281.11","first-page":"979","article-title":"Study on the clinical characteristics of systemic sclerosis","volume":"57","author":"Kang","year":"1999","journal-title":"Korean J Med"},{"key":"2018112909385987000_45.9.1281.12","first-page":"243","article-title":"The clinical features and autoantibody profile of progressive systemic sclerosis in Korea","volume":"8","author":"Park","year":"2001","journal-title":"J Korean Rheum Assoc"},{"key":"2018112909385987000_45.9.1281.13","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-009-1324-7"},{"key":"2018112909385987000_45.9.1281.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230510"},{"key":"2018112909385987000_45.9.1281.15","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"key":"2018112909385987000_45.9.1281.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.38098"},{"key":"2018112909385987000_45.9.1281.17","doi-asserted-by":"crossref","first-page":"e0163894","DOI":"10.1371\/journal.pone.0163894","article-title":"Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study","volume":"11","author":"Jaeger","year":"2016","journal-title":"PLoS One"},{"key":"2018112909385987000_45.9.1281.18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg033"},{"key":"2018112909385987000_45.9.1281.19","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90986-0"},{"key":"2018112909385987000_45.9.1281.20","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-011-1751-0"},{"key":"2018112909385987000_45.9.1281.21","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160106"},{"key":"2018112909385987000_45.9.1281.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200275"},{"issue":"Suppl 91","key":"2018112909385987000_45.9.1281.23","first-page":"S31","article-title":"Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis","volume":"4","author":"Ochoa","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909385987000_45.9.1281.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)00023-5"},{"key":"2018112909385987000_45.9.1281.25","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"2018112909385987000_45.9.1281.26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09861.x"},{"key":"2018112909385987000_45.9.1281.27","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes303"},{"key":"2018112909385987000_45.9.1281.28","doi-asserted-by":"crossref","first-page":"625","DOI":"10.14740\/jocmr2606w","article-title":"Systemic sclerosis and malignancy: a review of current data","volume":"8","author":"Zeineddine","year":"2016","journal-title":"J Clin Med Res"},{"key":"2018112909385987000_45.9.1281.29","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s12885-016-2444-5","article-title":"Survival rates of cancer patients with and without rheumatic disease: a retrospective cohort analysis","volume":"16","author":"Park","year":"2016","journal-title":"BMC Cancer"},{"key":"2018112909385987000_45.9.1281.30","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/s13075-014-0428-x","article-title":"Comparison of cancer incidence among patients with rheumatic disease: a retrospective cohort study","volume":"16","author":"Chang","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2018112909385987000_45.9.1281.31","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.autrev.2017.03.012","article-title":"Novel risk factors related to cancer in scleroderma","volume":"16","author":"Bernal-Bello","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2018112909385987000_45.9.1281.32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5301\/jsrd.5000250","article-title":"Mechanistic and clinical insights at the scleroderma-cancer interface","volume":"2","author":"Shah","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"2018112909385987000_45.9.1281.33","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1111\/bjd.15838","article-title":"Incidence, prevalence, mortality and causes of death in systemic sclerosis in Korea: a nationwide population-based study","volume":"178","author":"Kang","year":"2018","journal-title":"Br J Dermatol"},{"key":"2018112909385987000_45.9.1281.34","doi-asserted-by":"crossref","first-page":"292","DOI":"10.4143\/crt.2017.118","article-title":"Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2014","volume":"49","author":"Jung","year":"2017","journal-title":"Cancer Res Treat"},{"issue":"Suppl 106","key":"2018112909385987000_45.9.1281.35","first-page":"40","article-title":"Changes in the pattern of death of 987 patients with systemic sclerosis from 1990 to 2009 from the nationwide Spanish Scleroderma Registry (RESCLE)","volume":"35","author":"Rubio-Rivas","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909385987000_45.9.1281.36","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.066068"},{"key":"2018112909385987000_45.9.1281.37","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100298"},{"key":"2018112909385987000_45.9.1281.38","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ijcard.2017.02.086","article-title":"Incidence, prevalence, mortality and causes of death in Takayasu Arteritis in Korea - a nationwide, population-based study","volume":"235","author":"Park","year":"2017","journal-title":"Int J Cardiol"},{"key":"2018112909385987000_45.9.1281.39","doi-asserted-by":"crossref","first-page":"e2014017","DOI":"10.4178\/epih\/e2014017","article-title":"Prevalence of fungal infections using National Health Insurance data from 2009\u20132013, South Korea","volume":"36","author":"Yoon","year":"2014","journal-title":"Epidemiol Health"},{"key":"2018112909385987000_45.9.1281.40","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211448"},{"key":"2018112909385987000_45.9.1281.41","doi-asserted-by":"crossref","first-page":"e1728","DOI":"10.1097\/MD.0000000000001728","article-title":"Registry of the Spanish Network for systemic sclerosis: survival, prognostic factors, and causes of death","volume":"94","author":"Simeon-Aznar","year":"2015","journal-title":"Medicine"},{"key":"2018112909385987000_45.9.1281.42","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-012-2145-7"},{"key":"2018112909385987000_45.9.1281.43","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/1756-185X.12322","article-title":"Clinical and autoantibody profile in systemic sclerosis: baseline characteristics from a West Malaysian cohort","volume":"18","author":"Sujau","year":"2015","journal-title":"Int J Rheum Dis"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.171443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T19:30:43Z","timestamp":1543519843000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.171443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,15]]},"references-count":43,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,9,1]]},"published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.3899\/jrheum.171443"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.171443","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,15]]}}}